PHS2019-02 Omnibus Solic of the NIH, CDC, and FDA for SBIR Apps No Clinical Trial (Parent SBIR R43/4
PHS2019-02 NIH、CDC 和 FDA 的 SBIR 应用程序综合 Solic 尚未进行临床试验(母公司 SBIR R43/4
基本信息
- 批准号:10476977
- 负责人:
- 金额:$ 48.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Field Detection of arboviruses directly from mosquito traps
Firebird Biomolecular Sciences, LLC.
Abstract
Mosquitoes are the world's deadliest creatures. In the US, mosquitoes are vectors for West Nile, many kinds
of encephalitis, and viruses arriving Latin America and Africa. In the developing world, they cause millions of
cases of disease and death each year. Routine insect spraying is not a "fix", as it leads to pesticide resistance,
encounters public opposition, and destroys beneficial insects. Thus, the EPA, CDC, ECDPC, and their
counterparts around the globe, strongly recommend surveillance before spraying. Florida law requires it.
In Phase 1, we created (a) innovative technology to generate CO2 to attract mosquitoes, (b) innovative tech-
nology to collect viral RNA from the attracted mosquitoes, (c) data showing that collected RNA is stable under
Florida summer conditions for at least 3 days, (d) processes where captured viral RNA is amplified directly
without handling mosquitos or Qiagen RNA preps, and (e) reagents that allow robust multiplex amplification.
These specs, which can transform the science and practice of arbovirus surveillance, attracted TrakITNow, an
innovator in instrument design. Its award-winning trap (Moskeet) counts and speciates mosquitoes, doing
everything short of collecting samples from the mosquitoes and determining if these hold arboviruses.
This Phase 2 project will re-configure and metric the Phase 1 innovations to allow them, in Phase 3, to be
placed on Moskeet in two operational architectures (OA1 and OA2). A series of improvement and adaptations
will be evaluated using tightly crafted metrics in two Aims. Meeting these metrica will trigger a commitment by
TrakITNow to support Phase 3 funding to launch a combined product,
Aim 1 will develop and metric Firebird's chemistry for an OA1 architecture that will convert Moskeet from a
trap-count-speciate-communicate product into a trap-count-speciate-sample-communicate product. This will
exploit Firebird's Phase 1 innovation (SterileQTM) that autonomously traps and stabilizes viral RNA. Different
baits, RNA-stabilizing preservatives, and pre-amplification enzymes will be metricked to create, at the end of
Year 1, a Moskeet-ready OA1 chemistry that allows continuous sampling of mosquitoes. Metrics include (a)
>50% of infected mosquitoes leaving detectable sample, (b) >200 hours half-life of RNA, and (c) capture of >1
pg of RNA. An instrument from Insilixa (Hydra), also enhanced by Firebird's reagents, will be used for on-site
virus detection. Hydra is portable, and its low complexity design allows it to be used by amateurs.
Aim 2 will develop and metric Firebird's chemistry for an OA2 architecture. This will convert Moskeet into a
trap-count-speciate-sample-analyze-communicate product. Here, we will develop and benchmark point-of-
sampling amplification tools, specifically: (a) RT-PCR, and (b) loop amplification (LAMP). These will, as
needed, incorporate reagent innovations (AEGIS, SAMRS, Biversals) to support highly multiplexed detection of
arboviruses, create uniform amplification of multiple analytes, manage primer-primer products, prevent loss of
PCR resources to off-target processes that create "monsters", and manage arbovirus sequence divergence.
直接从诱蚊器中实地检测虫媒病毒
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN A BENNER其他文献
STEVEN A BENNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN A BENNER', 18)}}的其他基金
Basic Research for Diagnostics and Surveillance in Lower Resource Environments
低资源环境诊断和监测基础研究
- 批准号:
10669039 - 财政年份:2021
- 资助金额:
$ 48.52万 - 项目类别:
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10626917 - 财政年份:2021
- 资助金额:
$ 48.52万 - 项目类别:
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10478279 - 财政年份:2021
- 资助金额:
$ 48.52万 - 项目类别:
Basic Research for Diagnostics and Surveillance in Lower Resource Environments
低资源环境诊断和监测基础研究
- 批准号:
10468606 - 财政年份:2021
- 资助金额:
$ 48.52万 - 项目类别:
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10298982 - 财政年份:2021
- 资助金额:
$ 48.52万 - 项目类别:
Equipment Supplement to 1R01GM141391-01A1 (Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins)
1R01GM141391-01A1 的设备补充(易于使用的试剂盒,用于进化共价标记和灭活蛋白质的试剂)
- 批准号:
10580301 - 财政年份:2021
- 资助金额:
$ 48.52万 - 项目类别:
Reagents to Chemically Tag Specific Coronavirus Spike Proteins
化学标记特定冠状病毒刺突蛋白的试剂
- 批准号:
10259048 - 财政年份:2021
- 资助金额:
$ 48.52万 - 项目类别:
相似国自然基金
手性壳聚糖噁唑啉催化材料的制备及在连续流反应中的应用
- 批准号:JCZRYB202501227
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
微波响应性植入体涂层的研发及其对感染性骨缺损的治疗与机制研究
- 批准号:JCZRLH202500568
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
电视三维文博馆数字建模及渲染关键技术
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
重庆“416”科技创新布局与产业创新协同推进的战略研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于压电效应的路面能量收集协同增强方法
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
非自治迭代函数系统拓扑熵与拓扑压的研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
面向复杂场景的高端工业运维软件
- 批准号:2025C01059
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于多模态混合专家模型的点云配准技术研究
- 批准号:2025JJ50338
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
面向旋转机构的深度学习故障智能诊断算法研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
氧化物修饰TiO2异质结的制备及光催化降解染料废水的研究
- 批准号:2025JJ70371
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
牛白血病ウイルス抵抗性牛の簡易判別診断法の開発
开发一种简单的诊断方法来识别牛对牛白血病病毒的抵抗力
- 批准号:
22KJ2524 - 财政年份:2023
- 资助金额:
$ 48.52万 - 项目类别:
Grant-in-Aid for JSPS Fellows
DSC MANAGEMENT AND SUPPORT FOR HELPING TO END ADDICTION LONG-TERM INITIATIVE (HEAL). 08/02/2023 - 08/01/2024. N01DA-22-2253. TASK ORDER 75N95023F00009 (TO13).
DSC 管理和支持帮助戒除成瘾长期计划(治愈)。
- 批准号:
10939542 - 财政年份:2023
- 资助金额:
$ 48.52万 - 项目类别:
PHASE I COCAINE DRUG INTERACTION STUDY. TO6. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 08/10/2023 - 02/09/2025. NIDA REF. NO. N01DA-19-8947.
第一阶段可卡因药物相互作用研究。
- 批准号:
10937276 - 财政年份:2023
- 资助金额:
$ 48.52万 - 项目类别:
NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 03/01/2023 - 02/29/2024. N01DA-22-2253. TASK ORDER 75N95023F00003 (TO7).
NIDA 数据、统计数据和临床试验支持中心管理和支持。
- 批准号:
10936243 - 财政年份:2023
- 资助金额:
$ 48.52万 - 项目类别:
SYNTHESIS AND DISTRIBUTION OF OPIOID AND RELATED PEPTIDES. PERIOD OF PERFORMANCE: 02/15/2023-02/14/2024. N01DA-22-8963.
阿片类药物及相关肽的合成和分布。
- 批准号:
10937593 - 财政年份:2023
- 资助金额:
$ 48.52万 - 项目类别:
NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 03/01/2022 - 02/28/2023. N01DA-19-2250. TASK ORDER 75N95022F00001 (TO
NIDA 数据、统计数据和临床试验支持中心管理和支持。
- 批准号:
10720981 - 财政年份:2022
- 资助金额:
$ 48.52万 - 项目类别:
101079778 — DANUBIUS IP — HORIZON-INFRA-2021-DEV-02
101079778 — DANUBIUS IP — HORIZON-INFRA-2021-DEV-02
- 批准号:
10058146 - 财政年份:2022
- 资助金额:
$ 48.52万 - 项目类别:
EU-Funded
Horizon Europe (HORIZON) Call: HORIZON-INFRA-2021-DEV-02 Project: 101079773 — EuPRAXIA ESFRI Project Preparatory Phase
Horizon Europe (HORIZON) 电话:HORIZON-INFRA-2021-DEV-02 项目:101079773 → EuPRAXIA ESFRI 项目准备阶段
- 批准号:
10062954 - 财政年份:2022
- 资助金额:
$ 48.52万 - 项目类别:
EU-Funded
INTEGRATED CARE AND TREATMENT FOR SEVERE INFECTIOUS DISEASES AND SUBSTANCE USE DISORDERS (SUD) AMONG HOSPITALIZED PATIENTS (CTN-0121). 09/28/2022 - 02
住院患者中严重传染病和药物使用障碍 (SUD) 的综合护理和治疗 (CTN-0121)。
- 批准号:
10720986 - 财政年份:2022
- 资助金额:
$ 48.52万 - 项目类别:
PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA; NIDA REF. NO. N01DA-22-8959. 02/22/2022 - 02/21/2024.
NIDA 临床前药物发现和滥用责任测试;
- 批准号:
10937494 - 财政年份:2022
- 资助金额:
$ 48.52万 - 项目类别: